The estimated Net Worth of George L Sing is at least $144 Milión dollars as of 3 May 2024. Mr. Sing owns over 2,000 units of Regeneron Pharmaceuticals stock worth over $32,358,966 and over the last 21 years he sold REGN stock worth over $110,812,193. In addition, he makes $722,993 as Independent Director at Regeneron Pharmaceuticals.
George has made over 42 trades of the Regeneron Pharmaceuticals stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 2,000 units of REGN stock worth $826,660 on 3 May 2024.
The largest trade he's ever made was selling 61,000 units of Regeneron Pharmaceuticals stock on 20 August 2020 worth over $36,929,400. On average, George trades about 6,789 units every 119 days since 2004. As of 3 May 2024 he still owns at least 28,349 units of Regeneron Pharmaceuticals stock.
You can see the complete history of Mr. Sing stock trades at the bottom of the page.
George L. Sing serves as Independent Director of the Company. Since 1998, Mr. Sing has been a Managing Director of Lancet Capital, a venture capital investment firm in the healthcare field. In addition, since 2016, Mr. Sing has served as Chief Executive Officer of GanD, Inc., a biomedical drug development company. From 2004 to 2015, Mr. Sing served as Chief Executive Officer of Stemnion, Inc. (currently known as Noveome Biotherapeutics, Inc.), a biomedical company in the regenerative medicine field. Mr. Sing’s extensive healthcare and financial expertise as a healthcare venture capital investor and biomedical company chief executive officer, his executive leadership experience, and his substantial knowledge of the Company led the board to conclude that Mr. Sing should serve as a director.
As the Independent Director of Regeneron Pharmaceuticals, the total compensation of George Sing at Regeneron Pharmaceuticals is $722,993. There are 16 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.
George Sing is 70, he's been the Independent Director of Regeneron Pharmaceuticals since 1988. There are 2 older and 22 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis a Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: